Terms: = Brain cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
128 results:
1. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C
Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970
[No Abstract] [Full Text] [Related]
2. Site-specific mutagenesis screening in kras
Choi J; Shin JY; Kim TK; Kim K; Kim J; Jeon E; Park J; Han YD; Kim KA; Sim T; Kim HK; Kim HS
Cancer Lett; 2024 Jun; 591():216904. PubMed ID: 38642608
[TBL] [Abstract] [Full Text] [Related]
3. Targeting the molecular chaperone CCT2 inhibits GBM progression by influencing kras stability.
Zhao F; Yao Z; Li Y; Zhao W; Sun Y; Yang X; Zhao Z; Huang B; Wang J; Li X; Chen A
Cancer Lett; 2024 May; 590():216844. PubMed ID: 38582394
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
[TBL] [Abstract] [Full Text] [Related]
5. Recurrent primary intracranial sarcoma, DICER1-mutant in a pediatric patient with DICER1 syndrome: the importance of molecular testing.
Lachance A; Dimentberg E; Huang S; Bergeron-Gravel S; Bouffet É; Fonseca A; Crevier L; Saikali S; Bourget C; Giannakouros P; Faury D; Jabado N; Foulkes WD; Larouche V; Renzi S
Childs Nerv Syst; 2024 Jun; 40(6):1965-1969. PubMed ID: 38478067
[TBL] [Abstract] [Full Text] [Related]
6. Sotorasib in kras G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
[TBL] [Abstract] [Full Text] [Related]
7. Application of plasma circulating kras mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract] [Full Text] [Related]
8. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract] [Full Text] [Related]
9. kras is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract] [Full Text] [Related]
10. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
de Sauvage MA; Torrini C; Nieblas-Bedolla E; Summers EJ; Sullivan E; Zhang BS; Batchelor E; Marion B; Yamazawa E; Markson SC; Wakimoto H; Nayyar N; Brastianos PK
Neuro Oncol; 2024 May; 26(5):889-901. PubMed ID: 38134951
[TBL] [Abstract] [Full Text] [Related]
11. Brief report on the efficacy of sotorasib in kras-Mutated NSCLC patients with brain metastases.
Lebouille-Veldman AB; Taros TN; Nawabi NLA; Mekary RA; Peng L; Phillips J
Lung Cancer; 2024 Jan; 187():107425. PubMed ID: 38061200
[TBL] [Abstract] [Full Text] [Related]
12. Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric cancer by Liquid Biopsy.
Jung SH; Lee CK; Kwon WS; Yun S; Jung M; Kim HS; Chung HC; Chung YJ; Rha SY
Yonsei Med J; 2023 Sep; 64(9):531-540. PubMed ID: 37634629
[TBL] [Abstract] [Full Text] [Related]
13. Canadian Consensus Recommendations on the Management of kras G12C-Mutated NSCLC.
Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
[TBL] [Abstract] [Full Text] [Related]
14. Survival of patients with kras G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors.
Swart EM; Noordhof AL; Damhuis RAM; Kunst PWA; De Ruysscher DKM; Hendriks LEL; van Geffen WH; Aarts MJ
Lung Cancer; 2023 Aug; 182():107290. PubMed ID: 37419045
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase kras
Kettle JG; Bagal SK; Barratt D; Bodnarchuk MS; Boyd S; Braybrooke E; Breed J; Cassar DJ; Cosulich S; Davies M; Davies NL; Deng C; Eatherton A; Evans L; Feron LJ; Fillery S; Gleave ES; Goldberg FW; Cortés González MA; Guerot C; Haider A; Harlfinger S; Howells R; Jackson A; Johnström P; Kemmitt PD; Koers A; Kondrashov M; Lamont GM; Lamont S; Lewis HJ; Liu L; Mylrea M; Nash S; Niedbala MJ; Peter A; Phillips C; Pike K; Raubo P; Robb GR; Ross S; Sanders MG; Schou M; Simpson I; Steward O
J Med Chem; 2023 Jul; 66(13):9147-9160. PubMed ID: 37395055
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Alterations and the Incidence of brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis.
Gillespie CS; Mustafa MA; Richardson GE; Alam AM; Lee KS; Hughes DM; Escriu C; Zakaria R
J Thorac Oncol; 2023 Dec; 18(12):1703-1713. PubMed ID: 37392903
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study.
Ma K; Guo Q; Li X
BMC Pulm Med; 2023 May; 23(1):175. PubMed ID: 37208639
[TBL] [Abstract] [Full Text] [Related]
18. Update on Emerging Therapies for Advanced Colorectal cancer.
Alese OB; Wu C; Chapin WJ; Ulanja MB; Zheng-Lin B; Amankwah M; Eads J
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389574. PubMed ID: 37155942
[TBL] [Abstract] [Full Text] [Related]
19. Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report.
Ibrahimi AK; Al-Hussaini M; Laban DA; Ammarin R; Wehbeh L; Al-Mousa A
CNS Oncol; 2023 Jun; 12(2):CNS97. PubMed ID: 37129184
[TBL] [Abstract] [Full Text] [Related]
20. Genomic and transcriptomic profiling reveal molecular characteristics of parathyroid carcinoma.
Jo SY; Hong N; Lee S; Jeong JJ; Won J; Park J; Kim GJ; Kim SK; Kim S; Rhee Y
Exp Mol Med; 2023 May; 55(5):886-897. PubMed ID: 37121965
[TBL] [Abstract] [Full Text] [Related]
[Next]
